SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1982; 9: 2248.
  • 2
    Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 200917.
  • 3
    Van Leeuwen MA, van Rijswijk MH, van der Heijde DM, Te Meerman GJ, van Riel PL, Houtman PM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993; 32 Suppl 3: 913.
  • 4
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 5
    Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 72940.
  • 6
    Drossaers-Bakker KW, Zwinderman AH, Vlieland TP, van Zeben D, Vos K, Breedveld FC, et al. Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum 2002; 47: 38390.
  • 7
    Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004; 50: 208293.
  • 8
    Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003; 48: 4653.
  • 9
    De Vries-Bouwstra JK, Goekoop-Ruitermen YP, van Zeben D, Breedveld FC, Dijkmans BA, Hazes JM. A comparison of clinical and radiological outcomes of four treatment strategies for early rheumatoid arthritis: results of the Best Trial. Ann Rheum Dis 2004; 63 Suppl 1: S58.
  • 10
    Stenger AA, van Leeuwen MA, Houtman PM, Bruyn GA, Speerstra F, Barendsen BC, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998; 37: 115763.
  • 11
    Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 34756.
  • 12
    Van der Heijde DM, van 't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 17781.
  • 13
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 14
    Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 91620.
  • 15
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A Simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 24457.
  • 16
    Aletaha D, Stamm T, Smolen JS. Validation of the Simplified Disease Activity Index (SDAI) in an observational cohort of patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63 Suppl 1: S111.
  • 17
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Segurado OG. Assessment of disease activity and treatment response to adalimumab (HUMIRA) in RA with the Simplified Disease Activity Index (SDAI) [abstract]. Arthritis Rheum 2004; 50 Suppl 9: S1901.
  • 18
    Soubrier M, Zerkak D, Dougados M. Should we revisit the definition of higher disease activity state in rheumatoid arthritis (RA)? [abstract]. Arthritis Rheum 2004; 50 Suppl 9: S386.
  • 19
    Wong AL, Harker JO, Park GS, Paulus HE. Longitudinal measurement of RA disease activity in a clinical practice setting: usefulness of the SDAI [abstract]. Arthritis Rheum 2004; 50 Suppl: S3867.
  • 20
    Smolen JS. The work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Br J Rheumatol 1992; 31: 21920.
  • 21
    Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2: 47388.
  • 22
    Paulus HE. Defining remission in rheumatoid arthritis: what is it? Does it matter? J Rheumatol 2004; 31: 14.
  • 23
    Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995; 54: 9447.
  • 24
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 67581.
  • 25
    St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 343243.
  • 26
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 2639.
  • 27
    Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003; 21 Suppl 31: S20910.
  • 28
    Scott DL, van Riel PL, van der Heijde DM, Benke AS. Assessing disease activity in rheumatoid arthritis: the EULAR handbook of standard methods. Zurich: EULAR; 1993.
  • 29
    Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996; 35: 11015.
  • 30
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 31
    Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 15563.
  • 32
    Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis: an observational study. J Rheumatol 2002; 29: 16318.
  • 33
    Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002; 41: 136774.
  • 34
    Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 90614.
  • 35
    Cohen J. Weighted kappa: nominal scale agreement with provision for scale disagreement or partial credit. Psychol Bull 1968; 70: 21320.
  • 36
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 37
    Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977; 18: 48191.
  • 38
    Van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with “second-line” antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996; 124: 699707.
  • 39
    Lard LR, Visser H, Speyer I, van der Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 44651.
  • 40
    Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 30918.
  • 41
    Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003; 21 Suppl 31: S1547.
  • 42
    Aletaha D, Smolen JS. Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics. Curr Rheumatol Rep 2003; 5: 40912.
  • 43
    Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti–tumor necrosis factor α agents in rheumatoid arthritis. Arthritis Rheum 2003; 48: 3138.
  • 44
    Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 130815.
  • 45
    Van Riel PL, van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 2000; 59 Suppl 1: i2831.
  • 46
    Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004; 50: 3642.
  • 47
    Kirwan JR, Chaput de Saintonge DM, Joyce CR, Currey HL. Clinical judgment in rheumatoid arthritis. I. Rheumatologists' opinions and the development of ‘paper patients’. Ann Rheum Dis 1983; 42: 6447.